Ossiform

ApplicationOdense, DenmarkFounded 2017· One of 462 Application companies tracked by AMPulse

Develops and manufactures patient-specific, resorbable bone implants using a proprietary 3D printing technology that are replaced by the patient's own bone over time.

CEO / Founder: Thea Wulff Olesen
Team Size: 11-50
Stage: Active
Total Funding: $28.0M
Latest Round: Venture Round
Key Investors: West Hill Capital, Asimov Ventures, Vækstfonden (The Danish Growth Fund), PreSeed Ventures

Technology & Products

Key Products

P3D Scaffolds (for research use), Patient-specific bone implants (in development for clinical use), Ossi Ink (in partnership with CELLINK)

Technological Advantage

The ability to create customized, patient-specific implants on-demand provides a significant advantage over standard-sized metal or allograft implants, leading to better surgical outcomes and reduced surgery time. The technology is protected by a strong IP portfolio.

Differentiation

Value Proposition

Providing patient-matched, natural, and fully resorbable bone implants that improve surgical outcomes, reduce complications, and enhance bone regeneration compared to traditional implants.

How They Differentiate

Ossiform differentiates by offering fully resorbable, patient-specific implants made from a proprietary bioceramic that mimics natural bone, whereas many competitors focus on permanent metal (titanium) implants or allografts. Their focus on complete regeneration sets them apart.

Market & Competition

Target Customers

Hospitals, surgeons (orthopedic, maxillofacial, craniofacial), and medical research institutions.

Industry Verticals

Medical, Healthcare, Biotechnology

Competitors

Theradaptive, Ossio, MiMedx Group

Growth & Milestones

Growth Metrics

Expanding its team, securing international partnerships, and moving towards FDA clearance for its clinical products. The company has successfully launched its research-use products (P3D Scaffolds) globally.

Major Milestones

Founded in 2017 as a spinout from the University of Southern Denmark., Rebranded from Particle3D to Ossiform in early 2022., Secured multiple rounds of funding, including a significant round in October 2022., Established key strategic partnerships with CELLINK, Asimov Ventures, and CAM Bioceramics., Launched P3D Scaffolds for the global research market and developed Ossi Ink with CELLINK.

Notable Customers

Research institutions and universities worldwide using P3D Scaffolds. Clinical customers are anticipated upon regulatory approval.

https://www.ossiform.com

Why this company matters

AMPulse analysis, not a company disclosure

Ossiform occupies a niche position in the orthopedic and craniomaxillofacial implant market by offering fully resorbable, patient-matched implants. Unlike permanent metal or allograft alternatives, its implants are designed to be replaced by the patient's own bone, potentially reducing long-term complications and revision surgeries.

The company's core technology combines a proprietary beta-tricalcium phosphate biomaterial with a 3D printing process that creates porous, bone-like structures. This approach uses vat photopolymerization (VPP) and material extrusion (MEX) techniques to fabricate implants that match each patient's anatomy. Ossiform's product line includes P3D Scaffolds for research use, patient-specific implants in clinical development, and Ossi Ink, a printable bioink developed in partnership with CELLINK.

Target customers include hospitals and surgeons in orthopedic, maxillofacial, and craniofacial specialties, as well as medical research institutions. The company has launched P3D Scaffolds globally for research applications, while clinical use awaits regulatory clearance. Key partnerships with CELLINK, Asimov Ventures, and CAM Bioceramics support material development, U.S. market entry, and medical-grade ceramic powder supply.

Ossiform's strategic moat rests on its patented 3D printing technology and proprietary bioceramic formulation, which together enable full resorbability and natural bone regeneration. The company has raised $28 million from investors including West Hill Capital, Asimov Ventures, and Vækstfonden. A key open question is how quickly it can achieve FDA clearance and scale clinical adoption against established competitors like Ossio and MiMedx Group.